BofA raised the firm’s price target on Goldman Sachs (GS) to $675 from $650 and keeps a Buy rating on the shares after its Q4 earnings beat.

BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

Profits at some of the biggest U.S. lenders rose in the fourth quarter as dealmaking picked up and trading was boosted by ...

BlackRock dropped out of the United Nations-backed climate change investing initiative, which was followed by NZAM suspending ...

JERICHO, N.Y., Jan. 15, 2025 /PRNewswire/ -- The Virgam Agency, a leader in experiential marketing innovation, announces a ...

“If North America replaces 10% of the imports we are getting from China, and we make them in North America, Mexico’s GDP ...

Some of the world's biggest polluters are reaping billions of dollars through a lax form of green finance, a new ...

A federal judge in Texas ruled that the company violated its ERISA duties by not focusing “on the best financial benefit” for ...

Los Angeles firefighters braced on Tuesday for a new round of intense winds that could fuel two monstrous wildfires that have ...

Bank of America is set to become the official banking partner of all 27 national soccer teams in the United States, after the ...

Financial institutions must store their communications. Some employees fail to do so. Eight financial institutions pay a fine ...